Pre-clinically, treatment with MI such as SNDX-5613 or its combinations with venetoclax or FLT3 inhibitors has been shown to exert significant in vivo activity in PDX models of AML with mtNPM1 with or without FLT3 mutation [22, 24, 25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.